Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Jane M. Grant-Kels MD, FAAD Advisory Board

Ashish C. Bhatia MD, FAAD Associate Editor

Robert T. Brodell MD, FAAD Editor-in-Chief

See All Experts

featured

Published in Dermatology

Journal Scan / Research · March 04, 2019

Efficacy and Safety of Switching to Ixekizumab in Secukinumab Nonresponder Patients With Psoriasis

The British Journal of Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Robert Brodell MD, FAAD

The British Journal of Dermatology

Efficacy and Safety of Switching to Ixekizumab in Secukinumab Nonresponder Patients With Psoriasis: Results From a Multicentre Experience

Br J Dermatol 2018 Dec 22;[EPub Ahead of Print], A Conti, F Peccerillo, P Amerio, A Balato, F Bardazzi, L Bianchi, M Burlando, SP Cannavò, A Chiricozzi, P Dapavo, C De Simone, MC Fargnoli, A Gambardella, P Gisondi, P Malagoli, G Malara, C Mugheddu, AM Offidani, S Piaserico, F Prignano, L Stingeni, G Pellacani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Efficacy and Safety of Switching to Ixekizumab in Secukinumab Nonresponder Patients With Psoriasis

Additional Info

Efficacy and Safety of Switching to Ixekizumab in Secukinumab Nonresponder Patients With Psoriasis: Results From a Multicentre Experience

Further Reading

Rebound Growth of Infantile Hemangiomas After Discontinuation of Treatment With Propranolol vs Atenolol

Allergic Contact Cheilitis/Stomatitis Owing to Beverages and Food

Assessing Skin Cancer Diagnosis Accuracy by Lesion Type, Physician Experience, and Examination Method

Doxycycline Post-Exposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

Local Recurrence, Metastasis, and Mortality Rates Among Patients With Thin and In Situ Melanomas

Suicidal and Self-Injurious Behaviors Among Patients With Psoriasis or Psoriatic Arthritis Treated With Biologics

Efficacy and Safety of Combined Topical 17α-Ethinyl Estradiol With Minoxidil vs Topical Minoxidil Alone in Patients With Female Pattern Hair Loss

Clinical Features and Treatment Outcomes Among Patients With Primary Cutaneous B-Cell Lymphomas

Clinical Characteristics and Outcomes of DPP-4 Inhibitor–Associated Bullous Pemphigoid

Recently Updated